Last reviewed · How we verify
Nicorette TX
At a glance
| Generic name | Nicorette TX |
|---|---|
| Sponsor | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Empowering Cessation ACS South Region (PHASE1, PHASE2)
- Sympathovagal Balance in Smoking Cessation (PHASE4)
- "EASY EFFECTIVE SMOKELESS" With NICORETTE®
- Sustaining Smoking Cessation in Smokers With Kids With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicorette TX CI brief — competitive landscape report
- Nicorette TX updates RSS · CI watch RSS
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH portfolio CI